WO1996001324A3 - Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique - Google Patents
Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique Download PDFInfo
- Publication number
- WO1996001324A3 WO1996001324A3 PCT/FR1995/000894 FR9500894W WO9601324A3 WO 1996001324 A3 WO1996001324 A3 WO 1996001324A3 FR 9500894 W FR9500894 W FR 9500894W WO 9601324 A3 WO9601324 A3 WO 9601324A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- internal ribosome
- ribosome entry
- entry site
- vector containing
- containing same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
- Y10S977/803—Containing biological material in its interior
- Y10S977/804—Containing nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/600,999 US5925565A (en) | 1994-07-05 | 1995-07-05 | Internal ribosome entry site, vector containing it and therapeutic use |
EP95925007A EP0769062A2 (fr) | 1994-07-05 | 1995-07-05 | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
JP8503707A JPH10503644A (ja) | 1994-07-05 | 1995-07-05 | 新規な内部リボソーム侵入部位、これを含むベクター、および治療への使用 |
AU29295/95A AU707874B2 (en) | 1994-07-05 | 1995-07-05 | New internal ribosome entry site, vector containing it and therapeutical use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9408300A FR2722208B1 (fr) | 1994-07-05 | 1994-07-05 | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
FR94/08300 | 1994-07-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996001324A2 WO1996001324A2 (fr) | 1996-01-18 |
WO1996001324A3 true WO1996001324A3 (fr) | 1996-02-29 |
Family
ID=9465025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1995/000894 WO1996001324A2 (fr) | 1994-07-05 | 1995-07-05 | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
Country Status (7)
Country | Link |
---|---|
US (1) | US5925565A (fr) |
EP (1) | EP0769062A2 (fr) |
JP (1) | JPH10503644A (fr) |
AU (1) | AU707874B2 (fr) |
CA (1) | CA2194155A1 (fr) |
FR (1) | FR2722208B1 (fr) |
WO (1) | WO1996001324A2 (fr) |
Families Citing this family (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605712B1 (en) * | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
US20030215795A1 (en) * | 1991-06-28 | 2003-11-20 | Frey Teryl K. | Highly infectious rubella virus DNA constructs and methods of production |
US6958237B2 (en) | 1991-06-28 | 2005-10-25 | Georgia State Univesity Research Foundation, Inc. | Highly infectious rubella virus DNA constructs and methods of production |
DE19514310A1 (de) * | 1995-04-18 | 1996-10-24 | Univ Ludwigs Albert | Vektoren zur Transfektion von eukaryotischen Zellen, deren Verwendung und damit transfizierte Zielzellen |
FR2747046B1 (fr) * | 1996-04-05 | 1998-06-19 | Univ Paris Curie | Nouveaux vaccins issus de plasmovirus |
FR2755975B1 (fr) * | 1996-11-15 | 1999-05-07 | Rhone Poulenc Rorer Sa | Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies |
FR2757061B1 (fr) * | 1996-12-16 | 1999-03-26 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire |
FR2762615B1 (fr) * | 1997-04-28 | 1999-07-16 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes et vecteur le contenant |
FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
AU1591099A (en) * | 1997-11-19 | 1999-06-07 | Nature Technology, Inc. | Chimeric viral packaging signal without (gag) gene sequences |
US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
AU767880B2 (en) * | 1998-03-16 | 2003-11-27 | Introgen Therapeutics, Inc. | Multigene vectors |
AU1128400A (en) | 1998-10-22 | 2000-05-08 | Medical College Of Georgia Institute, Inc. | Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors |
US6924099B1 (en) * | 1999-01-29 | 2005-08-02 | G.D. Searle & Co. | Biomarkers and assays for carcinogenesis |
EP1173597A1 (fr) * | 1999-04-29 | 2002-01-23 | Aarhus University | Expression de genes heterologues, a partir d'une cassette de traduction ires, dans des vecteurs retroviraux |
CN100352921C (zh) | 1999-05-06 | 2007-12-05 | 威克福雷大学 | 用于鉴定引起免疫反应的抗原的组合物和方法 |
DE60045350D1 (de) | 1999-06-01 | 2011-01-20 | Baylor College Medicine | Zusammensetzungen und verfahren zur therapeutischen anwendung einer mit dem gen atonal assoziierten sequenz |
US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
DE60142615D1 (de) * | 2000-04-28 | 2010-09-02 | Mannkind Corp | Epitop-synchronisierung in antigen präsentierenden zellen |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
WO2002014492A2 (fr) * | 2000-08-14 | 2002-02-21 | Iogenetics, Llc | Bovins resistant au syndrome de la vache grasse |
AU2002215499A1 (en) * | 2000-09-15 | 2002-03-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Internal ribosome entry sites (ires) of errantiviruses and uses thereof |
US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
US8034791B2 (en) | 2001-04-06 | 2011-10-11 | The University Of Chicago | Activation of Egr-1 promoter by DNA damaging chemotherapeutics |
US20040242523A1 (en) * | 2003-03-06 | 2004-12-02 | Ana-Farber Cancer Institue And The Univiersity Of Chicago | Chemo-inducible cancer gene therapy |
EP1390075B1 (fr) * | 2001-04-06 | 2012-01-18 | The University of Chicago | Induction chimiotherapeutique de l'activite du promoteur egr-1 dans la therapie genique |
EP1412493B1 (fr) | 2001-08-02 | 2011-10-05 | Institut Clayton De La Recherche | Procedes et compositions relatifs a des systemes production ameliores de vecteurs lentiviraux |
US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
US20030129203A1 (en) * | 2001-08-27 | 2003-07-10 | Nautilus Biotech S.A. | Mutant recombinant adeno-associated viruses |
AU2002324909A1 (en) * | 2001-09-07 | 2003-03-24 | Baylor College Of Medicine | Linear dna fragments for gene expression |
IL161229A0 (en) * | 2001-10-02 | 2004-09-27 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications. |
WO2003038112A2 (fr) | 2001-10-26 | 2003-05-08 | Baylor College Of Medicine | Composition et methode permettant de modifier la masse maigre et les proprietes osseuses d'un sujet |
WO2003040690A2 (fr) * | 2001-11-02 | 2003-05-15 | Rice University | Systeme de recyclage permettant la manipulation de la disponibilite intracellulaire du nadh |
CN1313617C (zh) * | 2001-11-07 | 2007-05-02 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
US20030157641A1 (en) * | 2001-11-16 | 2003-08-21 | Idec Pharmaceuticals Corporation | Polycistronic expression of antibodies |
US7241744B2 (en) | 2001-12-11 | 2007-07-10 | Baylor College Of Medicine | Treating anemia in subjects by administration of plasmids encoding growth hormone releasing hormone |
US20030224404A1 (en) * | 2002-02-25 | 2003-12-04 | Manuel Vega | High throughput directed evolution of nucleic acids by rational mutagenesis |
JP4343708B2 (ja) * | 2002-04-26 | 2009-10-14 | アンスティテュ ナシナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル−イ.エヌ.エス.ウ.エール.エム. | 改良型キメラ糖タンパク質と、類型化されたレンチウイルス |
EP1501861A4 (fr) | 2002-05-06 | 2007-06-20 | Univ Texas | Ciblage de proteines pour l'apport de reactifs therapeutiques ou de diagnostic |
EP2269619A1 (fr) | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | Procédés et compositions concernant des poxvirus et le cancer |
US20050202438A1 (en) * | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
AU2003263552A1 (en) * | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
WO2004048583A2 (fr) * | 2002-11-22 | 2004-06-10 | Institut Clayton De La Recherche | Compositions et systemes destines a la regulation genique |
WO2004073641A2 (fr) | 2003-02-18 | 2004-09-02 | Kevin Slawin | Activation induite dans des cellules dendritiques |
EP1603945A2 (fr) | 2003-03-12 | 2005-12-14 | Advisys, Inc. | Suplementation d'igf-i avec mediation par plasmide pour applications therapeutiques |
TW200424214A (en) * | 2003-04-21 | 2004-11-16 | Advisys Inc | Plasmid mediated GHRH supplementation for renal failures |
US20070224615A1 (en) * | 2003-07-09 | 2007-09-27 | Invitrogen Corporation | Methods for assaying protein-protein interactions |
CA2531698A1 (fr) | 2003-07-09 | 2005-01-27 | Sentigen Biosciences, Inc. | Methode de detection d'une interaction proteine-proteine |
KR101062140B1 (ko) | 2003-07-21 | 2011-09-05 | 트랜스진 에스.에이. | 향상된 시토신 디아미네이즈 활성을 갖는 폴리펩티드 |
WO2005047473A2 (fr) * | 2003-11-10 | 2005-05-26 | Emory University | Bitherapie genique a un seul vecteur pour hypertension pulmonaire |
EP1711187B1 (fr) | 2003-12-31 | 2010-05-12 | VGX Pharmaceuticals, LLC | Reduction de l'arthrite et de la boiterie chez des sujets par apport complementaire de somatostatine (srif) |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
EP1910550A4 (fr) | 2005-07-21 | 2009-11-04 | Abbott Lab | Expression multigenique comprenant des constructions sorf et methodes faisant appel a des polyproteines, a des pro-proteines, et a une proteolysis |
US20070026012A1 (en) | 2005-08-01 | 2007-02-01 | Cornell Research Foundation, Inc. | Compositions and methods for monitoring and altering protein folding and solubility |
US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
US20090317421A1 (en) | 2006-01-18 | 2009-12-24 | Dominique Missiakas | Compositions and methods related to staphylococcal bacterium proteins |
US20080096228A1 (en) * | 2006-08-08 | 2008-04-24 | The Regents Of The University Of California | Compositions And Methods Relating To Mammalian Internal Ribosome Entry Sites |
CN102026645B (zh) | 2006-09-15 | 2016-01-27 | 渥太华医院研究机构 | 溶瘤弹状病毒 |
WO2008049113A2 (fr) | 2006-10-19 | 2008-04-24 | Baylor College Of Medicine | Procédés et compositions pour générer une réponse immune en induisant des récepteurs cd40 et des récepteurs de reconnaissance de structures et des adaptateurs de ceux-ci |
KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
CN101743306A (zh) | 2007-03-23 | 2010-06-16 | 威斯康星校友研究基金会 | 体细胞重编程 |
EP2944649A1 (fr) | 2008-01-10 | 2015-11-18 | Research Development Foundation | Vaccins et diagnostics pour les ehrlichioses |
JP2011512877A (ja) * | 2008-03-12 | 2011-04-28 | ワイス・エルエルシー | 組換えタンパク質の大スケール産生に適した細胞を同定する方法 |
US8450112B2 (en) | 2008-04-09 | 2013-05-28 | Maxcyte, Inc. | Engineering and delivery of therapeutic compositions of freshly isolated cells |
ES2587395T3 (es) | 2008-06-04 | 2016-10-24 | Cellular Dynamics International, Inc. | Procedimientos para la producción de células IPS usando un enfoque no vírico |
WO2010019569A1 (fr) | 2008-08-12 | 2010-02-18 | Cellular Dynamics International. Inc. | Procédés de production de cellules ips |
EP2328603A4 (fr) | 2008-08-18 | 2013-01-02 | Univ Maryland | Dérivés d'apf et méthodes d'utilisation afférentes |
AU2009292996B2 (en) | 2008-09-22 | 2015-04-23 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters |
EP2341929B1 (fr) | 2008-10-06 | 2017-01-25 | University Of Chicago | Compositions et procédés associés aux protéines bactériennes emp |
HUE057713T2 (hu) | 2009-04-03 | 2022-05-28 | Univ Chicago | A protein A (SPA) variánsaival kapcsolatos készítmények és módszerek |
CN102459575A (zh) | 2009-06-05 | 2012-05-16 | 细胞动力国际有限公司 | 重编程t细胞和造血细胞的方法 |
ES2848650T3 (es) | 2009-09-14 | 2021-08-11 | Sillajen Biotherapeutics Inc | Terapia combinada contra el cáncer con virus vaccinia oncolítico |
CN102812040A (zh) * | 2009-10-30 | 2012-12-05 | 雅培制药有限公司 | Sorf构建体和多基因表达 |
AU2010329551B2 (en) | 2009-12-10 | 2016-02-11 | Turnstone Limited Partnership | Oncolytic rhabdovirus |
US10080799B2 (en) | 2010-02-12 | 2018-09-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions related to glycoprotein-immunoglobulin fusions |
CA2793424A1 (fr) | 2010-03-18 | 2011-09-22 | Cornell University | Preparation d'anticorps correctement plies utilisant la presentation sur la membrane interieure d'intermediaires de translocation twin-arginine |
JP2013523818A (ja) | 2010-04-05 | 2013-06-17 | ザ・ユニバーシティー・オブ・シカゴ | 免疫反応のエンハンサーとしてのプロテインA(SpA)抗体に関連する組成物および方法 |
WO2011133512A1 (fr) | 2010-04-19 | 2011-10-27 | Research Development Foundation | Variants de rtef-1 et utilisations de ceux-ci |
US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
US20110312001A1 (en) | 2010-06-15 | 2011-12-22 | Emile Nuwaysir | Compendium of ready-built stem cell models for interrogation of biological response |
JP5984217B2 (ja) | 2010-06-15 | 2016-09-06 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | 少量の末梢血からの人工多能性幹細胞の作製 |
WO2012003474A2 (fr) | 2010-07-02 | 2012-01-05 | The University Of Chicago | Compositions et méthodes associées à des variants de protéine a (spa) |
JP5897002B2 (ja) | 2010-07-07 | 2016-04-13 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | プログラミングによる内皮細胞の産生 |
EP2601289B1 (fr) | 2010-08-04 | 2017-07-12 | Cellular Dynamics International, Inc. | Reprogrammation des lymphocytes b immortalisés |
EP2613791A4 (fr) | 2010-09-08 | 2015-05-13 | Univ Texas | Thérapie anticancéreuse sur la base des récepteurs de la somatostatine |
US9095540B2 (en) | 2010-09-09 | 2015-08-04 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens |
EP2625271B1 (fr) * | 2010-10-04 | 2017-05-31 | Tree of Knowledge Patents B.V. | Méthode d'extraction d'adn de cellules végétales et de nématodes |
CN103429258B (zh) | 2011-01-04 | 2016-03-09 | 新罗杰公司 | 通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性 |
WO2012098260A1 (fr) | 2011-01-21 | 2012-07-26 | Axiogenesis Ag | Système non viral pour générer des cellules souches pluripotentes induites (ips) |
JP6005666B2 (ja) | 2011-02-08 | 2016-10-12 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | プログラミングによる造血前駆細胞の生産 |
US9085631B2 (en) | 2011-04-08 | 2015-07-21 | Nov Vac APS | Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
WO2012167382A1 (fr) | 2011-06-08 | 2012-12-13 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions et procédés pour le traitement du glioblastome |
CA2841165A1 (fr) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Procedes de reprogrammation cellulaire et d'ingenierie genomique |
WO2013026015A1 (fr) | 2011-08-18 | 2013-02-21 | Dana-Farber Cancer Institute, Inc. | Pièges de ligand de muc1 pour l'utilisation dans le traitement de cancers |
US9273102B2 (en) | 2011-10-12 | 2016-03-01 | Niels Iversen Møller | Peptides derived from Campylobacter jejuni and their use in vaccination |
CN110042086A (zh) | 2012-02-02 | 2019-07-23 | 得克萨斯州大学系统董事会 | 表达异源肿瘤相关抗原的腺病毒 |
WO2013162746A1 (fr) | 2012-04-26 | 2013-10-31 | University Of Chicago | Antigènes des staphylocoques coagulase et leurs méthodes d'utilisation |
US10125373B2 (en) | 2013-01-22 | 2018-11-13 | Arizona Board Of Regents On Behalf Of Arizona State University | Geminiviral vector for expression of rituximab |
RU2684211C2 (ru) | 2013-02-21 | 2019-04-04 | Тёрнстоун Лимитед Партнершип | Композиция вакцины |
US20140242595A1 (en) | 2013-02-22 | 2014-08-28 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
US20160010094A1 (en) | 2013-03-01 | 2016-01-14 | University Of Pretoria | Transgenic cell selection |
US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
KR20150131218A (ko) | 2013-03-14 | 2015-11-24 | 벨리쿰 파마슈티컬스, 인크. | T 세포 증식의 제어 방법 |
EP3569253A1 (fr) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Procédés permettant d'induire une apoptose partielle en utilisant des polypeptides de caspase |
WO2015035395A1 (fr) | 2013-09-09 | 2015-03-12 | Figene, Llc | Thérapie génique pour la régénération de cellules de type chondrocytes ou cartilagineuses |
US20170002064A1 (en) | 2013-11-08 | 2017-01-05 | The Board Of Regents Of The University Of Texas System | Vh4 antibodies against gray matter neuron and astrocyte |
WO2015070050A1 (fr) | 2013-11-08 | 2015-05-14 | Baylor Research Institute | La localisation nucléaire de glp-1 stimule la régénération myocardique et entraîne la régression d'une insuffisance cardiaque |
SG10201907841UA (en) | 2013-11-22 | 2019-10-30 | Dnatrix Inc | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
EP4227685A3 (fr) | 2013-12-03 | 2024-02-28 | Evaxion Biotech A/S | Proteines et acides nucleiques utiles dans des vaccins ciblant staphylococcus aureus |
JP6908381B2 (ja) | 2014-01-29 | 2021-07-28 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Muc1−c/細胞外ドメイン(muc1−c/ecd)に対する抗体 |
EP3104866A4 (fr) | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Méthodes d'activation des lymphocytes t à l'aide d'un polypeptide chimère inductible |
WO2015157636A1 (fr) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Expansion améliorée des lymphocytes infiltrants des tumeurs pour thérapie cellulaire adoptive |
WO2015164228A1 (fr) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Production d'hépatocytes par programmation progressive par génie génétique et chimique combinés |
US20170137800A1 (en) | 2014-07-08 | 2017-05-18 | The Children's Medical Center Corporation | Compositions and methods for treating diabetes |
AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
ES2904301T3 (es) | 2014-11-03 | 2022-04-04 | Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum | Receptores de células T dirigidos contra Bob1 y usos de los mismos |
US20180169211A1 (en) | 2014-11-13 | 2018-06-21 | Evaxion Biotech Aps | Peptides derived from acinetobacter baumannii and their use in vaccination |
EP3224362A4 (fr) | 2014-11-26 | 2018-06-06 | The Regents of The University of California | Compositions thérapeutiques comprenant des facteurs de transcription et leurs procédés de préparation et d'utilisation |
DK3234145T3 (da) | 2014-12-15 | 2019-08-19 | Bellicum Pharmaceuticals Inc | Fremgangsmåde til kontrollered aktivering eller eliminering af terapeutiske celler |
US10434162B2 (en) | 2015-01-12 | 2019-10-08 | Evaxion Biotech Aps | Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae |
WO2016134293A1 (fr) | 2015-02-20 | 2016-08-25 | Baylor College Of Medicine | Inactivation de p63 pour le traitement de l'insuffisance cardiaque |
EP4201955A1 (fr) | 2015-03-10 | 2023-06-28 | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum | Récepteurs de lymphocytes t dirigés contre l'antigène exprimé préférentiellement du mélanome et leurs utilisations |
WO2017005670A1 (fr) | 2015-07-04 | 2017-01-12 | Evaxion Biotech Aps | Protéines et acides nucléiques utiles dans des vaccins ciblant pseudomonas aeruginosa |
WO2017070337A1 (fr) | 2015-10-20 | 2017-04-27 | Cellular Dynamics International, Inc. | Procédés de différenciation dirigée de cellules souches pluripotentes en cellules immunes |
WO2017075395A1 (fr) | 2015-10-28 | 2017-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Vecteurs adénoviraux à spécificité tumorale et leurs utilisations thérapeutiques |
AU2016343682A1 (en) | 2015-10-30 | 2018-06-14 | The Regents Of The University Of California | Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells |
WO2017079202A1 (fr) | 2015-11-02 | 2017-05-11 | Board Of Regents, The University Of Texas System | Méthodes d'activation de cd40 et blocage de points de contrôle immunitaires |
WO2017079746A2 (fr) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Méthodes et compositions comprenant une thérapie génique suppressive de tumeur et le blocage du point de contrôle immunitaire pour le traitement du cancer |
CA3004438A1 (fr) | 2015-11-09 | 2017-05-18 | The Children's Hospital Of Philadelphia | Glypicane 2 a utiliser en tant que marqueur cancereux et cible therapeutique |
WO2017144523A1 (fr) | 2016-02-22 | 2017-08-31 | Evaxion Biotech Aps | Protéines et acides nucléiques utiles dans des vaccins ciblant staphylococcus aureus |
CA3019635A1 (fr) | 2016-03-31 | 2017-10-05 | Baylor Research Institute | Proteine 8 de type angiopoietine (angptl8) |
EP3463449A1 (fr) | 2016-05-27 | 2019-04-10 | ALK-Abelló A/S | Protéines immunogènes et fragments de celles-ci à partir d'acariens allergènes |
WO2017216384A1 (fr) | 2016-06-17 | 2017-12-21 | Evaxion Biotech Aps | Vaccination ciblant ichthyophthirius multifiliis |
WO2017220787A1 (fr) | 2016-06-24 | 2017-12-28 | Evaxion Biotech Aps | Vaccin contre l'infection provoquée par aeromonas salmonicida |
EP3478325A4 (fr) | 2016-07-01 | 2020-01-15 | Research Development Foundation | Élimination de cellules proliférantes de greffons dérivés de cellules souches |
EP3487872A1 (fr) | 2016-07-22 | 2019-05-29 | Evaxion Biotech ApS | Protéines chimériques pour induire une immunité vis-à-vis d'une infection à s. aureus |
AU2017340644B2 (en) | 2016-10-05 | 2024-05-09 | Fujifilm Cellular Dynamics Inc | Methods for directed differentiation of pluripotent stem cells to HLA homozygous immune cells |
CN110199020A (zh) | 2016-11-03 | 2019-09-03 | 坦普尔大学-高等教育联盟 | 用于快速产生用于细胞系开发的同源重组载体的dna质粒 |
CN109996809A (zh) | 2016-11-14 | 2019-07-09 | 诺华股份有限公司 | 与促融合蛋白minion相关的组合物、方法和治疗用途 |
WO2018111902A1 (fr) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Méthodes et compositions comprenant une thérapie génique virale et un inhibiteur de point de contrôle immunitaire pour le traitement et la prévention du cancer et des maladies infectieuses |
US11298420B2 (en) | 2016-12-21 | 2022-04-12 | Memgen, Llc | Armed oncolytic viruses |
EP3565578A1 (fr) | 2016-12-21 | 2019-11-13 | Memgen LLC | Adénovirus oncolytiques armés aptes à la réplication |
US11718648B2 (en) | 2017-01-05 | 2023-08-08 | Evaxion Biotech A/S | Vaccines targeting Pseudomonas aeruginosa |
DE102017103383A1 (de) | 2017-02-20 | 2018-08-23 | aReNA-Bio GbR (vertretungsberechtigter Gesellschafter: Dr. Heribert Bohlen, 50733 Köln) | System und Verfahren zur Zelltyp-spezifischen Translation von RNA-Molekülen in Eukaryoten |
EP3385373A1 (fr) | 2017-04-05 | 2018-10-10 | Centro de Neurociências e Biologia Celular | Compositions pour la reprogrammation de cellules en cellules dendritiques ou en cellules présentatrices d'antigènes, leurs procédés et utilisations |
CN110088272B (zh) | 2017-04-05 | 2023-08-04 | 阿斯加德治疗有限公司 | 用于将细胞重编程为树突状细胞或抗原呈递细胞的组合物、其方法和用途 |
ES2912383T3 (es) | 2017-04-18 | 2022-05-25 | Fujifilm Cellular Dynamics Inc | Células efectoras inmunitarias específicas de antígeno |
EP3621988A1 (fr) | 2017-05-09 | 2020-03-18 | Bellicum Pharmaceuticals, Inc. | Procédés pour augmenter ou modifier la transduction de signal |
CN110945018A (zh) | 2017-07-27 | 2020-03-31 | 诺华股份有限公司 | 抗脱落酶的trem2变体 |
EP3710466A2 (fr) | 2017-11-13 | 2020-09-23 | The University of Chicago | Méthodes et compositions pour le traitement des plaies |
WO2019145399A1 (fr) | 2018-01-24 | 2019-08-01 | Evaxion Biotech Aps | Vaccins pour la prophylaxie d'infections par s. aureus |
EP3768698A4 (fr) | 2018-03-19 | 2022-03-30 | MultiVir Inc. | Procédés et compositions comprenant une thérapie génique suppressive de tumeur et des agonistes de cd122/cd132 pour le traitement du cancer |
US11413336B2 (en) | 2018-03-23 | 2022-08-16 | Board Of Regents, The University Of Texas System | Coccidioides antigens and methods of their use |
WO2019211320A1 (fr) | 2018-05-01 | 2019-11-07 | Orfoneuro Aps | Traitement de la céroïde-lipofuscinose neuronale |
BR112021003897A2 (pt) | 2018-08-30 | 2021-05-25 | Tenaya Therapeutics, Inc. | reprogramação de células cardíacas com miocarina e asci1 |
WO2020083904A1 (fr) | 2018-10-22 | 2020-04-30 | Evaxion Biotech Aps | Vaccins ciblant m. catharrhalis |
EP3930687A4 (fr) | 2019-02-25 | 2023-06-07 | The University of Chicago | Méthodes et compositions destinées au traitement de maladies auto-immunes et inflammatoires faisant intervenir des peptides à affinité pour la matrice extracellulaire liés à des agents anti-inflammatoires |
WO2020174044A1 (fr) | 2019-02-27 | 2020-09-03 | Evaxion Biotech Aps | Vaccins ciblant h. influenzae |
EP3997226A1 (fr) | 2019-07-11 | 2022-05-18 | Tenaya Therapeutics, Inc. | Reprogrammation de cellules cardiaques avec des microarn et d'autres facteurs |
JP2022541538A (ja) | 2019-07-19 | 2022-09-26 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | グリピカン2結合ドメインを含有するキメラ抗原受容体 |
WO2021048381A1 (fr) | 2019-09-13 | 2021-03-18 | Evaxion Biotech Aps | Procédé d'identification de peptides de liaison au cmh stable par spectrométrie de masse |
WO2021048400A1 (fr) | 2019-09-13 | 2021-03-18 | Evaxion Biotech Aps | Procédé d'identification d'épitopes de lymphocytes t |
WO2021113644A1 (fr) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer |
EP4087593A1 (fr) | 2020-01-06 | 2022-11-16 | Evaxion Biotech A/S | Vaccins ciblant neisseria gonorrhoeae |
EP4114421A1 (fr) | 2020-03-02 | 2023-01-11 | Tenaya Therapeutics, Inc. | Régulation de vecteur génique au moyen de micro-arn exprimés par des cardiomyocytes |
US20230211023A1 (en) | 2020-03-25 | 2023-07-06 | Erasmus University Medical Center Rotterdam | Reporter system for radionuclide imaging |
CA3178949A1 (fr) | 2020-05-29 | 2021-12-02 | Andrew DIAS | Agregats cellulaires doubles de photorecepteurs et d'epithelium pigmente retinien et leurs procedes d'utilisation |
CA3180561A1 (fr) | 2020-05-29 | 2021-12-02 | Andrew DIAS | Bicouche d'epithelium pigmentaire retinien et de photorecepteurs et son utilisation |
AU2021360902A1 (en) | 2020-10-15 | 2023-04-27 | Aavocyte, Inc. | Recombinant adeno-associated virus vectors with cd14 promoter and use thereof |
EP4291216A1 (fr) | 2021-02-09 | 2023-12-20 | University of Houston System | Virus oncolytique pour administration systémique et les activités anti-tumorales améliorées |
CA3216719A1 (fr) | 2021-05-03 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Procedes de generation de cellules endotheliales corneennes matures |
KR20240005887A (ko) | 2021-05-07 | 2024-01-12 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | 성숙한 간세포를 발생시키는 방법 |
WO2022248531A1 (fr) | 2021-05-26 | 2022-12-01 | Evaxion Biotech A/S | Vaccination ciblant des pathogènes intracellulaires |
KR20240011831A (ko) | 2021-05-26 | 2024-01-26 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 만능 줄기 세포에서 유전자의 신속한 사일런싱을 방지하기 위한 방법 |
CA3224564A1 (fr) | 2021-07-05 | 2023-01-12 | Andreas Holm MATTSSON | Vaccins ciblant neisseria gonorrhoeae |
WO2023148398A1 (fr) | 2022-02-07 | 2023-08-10 | Var2 Pharmaceuticals Aps | Anticorps et fragments d'anticorps et analogues specifiques du sulfate de chondroïtine |
WO2023178191A1 (fr) | 2022-03-16 | 2023-09-21 | University Of Houston System | Système d'administration de gène hsv persistant |
WO2023201207A1 (fr) | 2022-04-11 | 2023-10-19 | Tenaya Therapeutics, Inc. | Virus adéno-associé comprenant une capside modifiée |
WO2023213393A1 (fr) | 2022-05-04 | 2023-11-09 | Evaxion Biotech A/S | Variants de protéine staphylococcique et parties tronquées |
WO2024006911A1 (fr) | 2022-06-29 | 2024-01-04 | FUJIFILM Holdings America Corporation | Astrocytes dérivés d'ipsc et leurs procédés d'utilisation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992007950A1 (fr) * | 1990-10-25 | 1992-05-14 | Clague Pitman Hodgson | Procede de transfert de genes au moyen de retrotransposons |
WO1993003143A1 (fr) * | 1991-08-07 | 1993-02-18 | Anderson W French | Vecteurs retroviraux contenant des sites internes d'entree de ribosome |
-
1994
- 1994-07-05 FR FR9408300A patent/FR2722208B1/fr not_active Expired - Fee Related
-
1995
- 1995-07-05 CA CA002194155A patent/CA2194155A1/fr not_active Abandoned
- 1995-07-05 AU AU29295/95A patent/AU707874B2/en not_active Ceased
- 1995-07-05 WO PCT/FR1995/000894 patent/WO1996001324A2/fr not_active Application Discontinuation
- 1995-07-05 EP EP95925007A patent/EP0769062A2/fr not_active Withdrawn
- 1995-07-05 JP JP8503707A patent/JPH10503644A/ja active Pending
- 1995-07-05 US US08/600,999 patent/US5925565A/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992007950A1 (fr) * | 1990-10-25 | 1992-05-14 | Clague Pitman Hodgson | Procede de transfert de genes au moyen de retrotransposons |
WO1993003143A1 (fr) * | 1991-08-07 | 1993-02-18 | Anderson W French | Vecteurs retroviraux contenant des sites internes d'entree de ribosome |
Non-Patent Citations (6)
Title |
---|
ADAMS, S. ET AL.: "Complete nucleotide sequence of a mouse VL30 retro-element", MOLECULAR AND CELLULAR BIOLOGY, vol. 8, no. 8, WASHINGTON US, pages 2989 - 2998 * |
HODGSON, C. ET AL.: "Expression of VL30 vectors in primary cell types which are targets for gene therapy", KEYSTONE SYMPOSIUM ON GENE THERAPY AND MOLECULAR MEDICINE, STEAMBOAT SPRINGS, COLORADO, USA, MARCH 26-APRIL 1, 1995. JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT 0 (21A). 1995. 408 * |
HODGSON, C. ET AL.: "Nucleotide sequence of mouse virus-like (VL30) retrotransposon BVL-1", NUCLEIC ACIDS RESEARCH, vol. 18, no. 3, OXFORD GB, pages 673 * |
HOMANN, H. ET AL.: "New generation of safe, efficient retroviral vectors and packaging cell lines for application in gene therapy trials.", KEYSTONE SYMPOSIUM ON GENE THERAPY AND MOLECULAR MEDICINE, STEAMBOAT SPRINGS, COLORADO, USA, MARCH 26-APRIL 1, 1995. JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT 0 (21A). 1995. 408 * |
TORRENT, C. ET AL.: "A small and efficient dimerization/packaging signal of rat VL30 RNA and its use in murine leukemia virus-VL30-derived vectors for gene transfer", JOURNAL OF VIROLOGY, vol. 68, no. 2, pages 661 - 667 * |
TORRENT, C. ET AL.: "Analytical study of rat retrotransposon VL30 RNA dimerization in vitro and packaging in murine leukemia virus.", JOURNAL OF MOLECULAR BIOLOGY 240 (5). 1994. 434-444 * |
Also Published As
Publication number | Publication date |
---|---|
EP0769062A2 (fr) | 1997-04-23 |
FR2722208B1 (fr) | 1996-10-04 |
AU707874B2 (en) | 1999-07-22 |
WO1996001324A2 (fr) | 1996-01-18 |
CA2194155A1 (fr) | 1996-01-18 |
US5925565A (en) | 1999-07-20 |
FR2722208A1 (fr) | 1996-01-12 |
JPH10503644A (ja) | 1998-04-07 |
AU2929595A (en) | 1996-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996001324A3 (fr) | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique | |
AU7321294A (en) | Transformed eukaryotic cells, and transposon-based transformation vectors | |
AU6909194A (en) | Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole | |
AU1108695A (en) | Aza-4-iminoquinolines, methods of preparing them and their use | |
HK1021602A1 (en) | Upper closure of a portable telephone and method of producing the upper closure of the portable telephone. | |
EP0656735A3 (fr) | Téléphone portable bimodal | |
AU4479897A (en) | Compositions including r-nsaids and therapeutic and prophylactic methods employing said compositions | |
AU6258394A (en) | Condensed nitrogen heterocycles, methods of preparing them and their use as pest-control agents, fungicides and antimycotics | |
EP0670895A4 (fr) | Clonage, expression et utilisations d'une nouvelle proteine secretee, la f-spondine. | |
EP0626174A3 (fr) | Procédé et composition de prophylaxie et/ou traitement de la hypofonction d'organes. | |
AU1245297A (en) | Preparation of 1,1,1,3,3-pentachlorobutane and 1,1,1,3,3-pentafluorobutane | |
AU5772396A (en) | 3,4-disubstituted-phenylsulphonamides and their therapeutic use | |
CA2222425A1 (fr) | Immortalisation et desimmortalisation de cellules | |
AU4939493A (en) | Posts, beams and the like, and method of making same | |
AU1487895A (en) | Copolymers of 1,4-dioxepan-2-one and 1,5,8,12- tetraoxacyclotetradecane -7-14-dione | |
WO1993000094A3 (fr) | Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine | |
AU7981594A (en) | Histamine h3-receptor antagonists and therapeutic uses thereof | |
AU5588194A (en) | Open cell foam structures, catalysts supported thereby and method of producing the same | |
WO1997012963A3 (fr) | Paf-acetylhydrolase paf et son utilisation en therapie | |
EP0675953A4 (fr) | Peptides solubles possedant une conformation secondaire contrainte en solution et procede de preparation de ces composes. | |
AU1027995A (en) | Expression system, integration vector and cell transformed by this integration vector | |
AU681204B2 (en) | N-substituted azabicycloalkane derivatives, their preparation and use | |
AU5107696A (en) | Cyclohexylamino and cyclohexylalkoxy nitrogen heterocycles, methods of preparing them and their use as pest-control agents and fungicides | |
AU7060594A (en) | Cloning and uses of the genetic locus bcl-6 | |
AU6496094A (en) | Tumor-associated antigens recognized by t cells and the uses of these antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08600999 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2194155 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995925007 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995925007 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995925007 Country of ref document: EP |